Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada

TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce the MyMedi.ca Integrated Healthcare Program (“Program”), a new program designed to integrate medical cannabis care and patient support into Canadian healthcare institutions and clinical networks.

The program extends the MyMedi.ca platform beyond traditional medical cannabis and referral channels and is intended to support hospitals, specialty clinics, multidisciplinary healthcare networks, insurers and other healthcare organizations seeking to incorporate structured medical cannabis pathways into their existing models of care. The Program extends access to a focused medical cannabis formulary, pharmacist-led patient support, healthcare provider (HCP) treatment planning and education as well as reimbursement and insurance.

“An important next step in the evolution of medical cannabis is furthering integration and access within established healthcare environments,” said Aras Azadian, Chief Executive Officer of Avicanna. “Building on a decade of research and collaboration with the Canadian medical community, this new Program further supports hospitals, clinics and healthcare networks, with the specialized infrastructure and support to incorporate medical cannabis into existing models of care. For patients, this opens additional access to HCP-led care, individualized treatment support and insurance coverage with the aim of improving treatment outcomes.”

Building on MyMedi.ca's Established Infrastructure and Proven Healthcare Integration 
The Program builds on Avicanna’s work with leading Canadian hospitals, healthcare institutions and medical professionals on clinical research and cannabinoid access. This includes the Sunnybrook Odette Cancer Centre pilot, which brought medical cannabis support into an established oncology setting and helped refine the patient pathways, educational frameworks and support models behind the program.

Addressing a Gap in Medical Cannabis Access
Medical cannabis use in Canada extends well beyond patients in the federally regulated medical access framework, with Health Canada’s 2024 Canadian Cannabis Survey reporting that only 18% of Canadians using cannabis for medical purposes did so with a medical document from a healthcare professional. This points to a gap in medically guided care, with many patients potentially managing symptoms without structured treatment planning, product and dosing guidance, medication review, reimbursement support or ongoing clinical follow-up.

The Company believes this integrated approach is designed to broaden access to HCP-guided medical cannabis care while maintaining continuity with patients' existing providers and supporting responsible, evidence-informed use. The Program may be implemented across several models, including:

• Hospital and institutional cannabinoid care programs
• Specialty and multidisciplinary clinic partnerships
• Integrated referral and patient-support pathways
• Insurer and payer-supported patient programs
• Healthcare-professional education and training
• Real-world evidence and research collaborations

About Avicanna Inc 
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. 

• Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. 
• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. 
• Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. 
• Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.

SOURCE Avicanna Inc.  

Stay Connected  
For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com. 

Cautionary Note Regarding Forward-Looking Information and Statements 
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.